BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bictegravir/lenacapavir (Bixlenvo) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bictegravir/lenacapavir (Bixlenvo)\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07908446-11020@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bictegravir/lenacapavir (Bixlenvo): Phase 4 readout est. (NCT079084
 46)
DESCRIPTION:Bictegravir/lenacapavir (Bixlenvo)\, phase 4\, HIV.\nStudy: Stu
 dy of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppres
 sed People With HIV\nEstimated primary completion: July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bictegravir-lenacapavir-bixlenvo#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0790
 8446
URL:https://assetmemo.bio/drug/bictegravir-lenacapavir-bixlenvo#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532656-11020@assetmemo.bio
DTSTAMP:20261121T005024Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Bictegravir/lenacapavir (Bixlenvo): Phase 2/3 readout est. (NCT0653
 2656)
DESCRIPTION:Bictegravir/lenacapavir (Bixlenvo)\, phase 2/3\, HIV.\nStudy: S
 tudy of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1\nEs
 timated primary completion: July 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bictegravir-lenacapavir-bixlenvo#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06532656
URL:https://assetmemo.bio/drug/bictegravir-lenacapavir-bixlenvo#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
